PAIN CONTROL > INJECTABLE ANESTHETICS Back to products list

Vivacaine®

Bupivacaine HCl. 0.5 % and Epinephrine 1:200,000 Injection, USP

Indications

  • Local dental anesthesia by infiltration or nerve block injections in adults.

Features & Benefits

  • Anesthesia may last two to three times longer than lidocaine and mepivacaine for dental use, in many patients up to 7 hours.
  • Onset of action is usually 2 to 10 minutes.
  • No-methylparaben formulation to avoid allergic reactions on sensitive patients.
  • Not made with natural rubber latex.
  • Terminal sterilization of product/cartridges for safe use.
  • Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage.
  • Cartridges packed 10 to a blister tray to avoid glass to glass contact, hence reducing breakage.

Presentation

  • Item#01A1600 – Box containing 5 blisters of 10 x 1.8 ml glass cartridges
  • Item#01A1610 – Box containing 1 blister of 10 x 1.8 ml glass cartridges

Risk Information

Reactions to Vivacaine® are characteristic of those used with other amide-type local anesthetics. A major cause of reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Vivacaine® is contraindicated in patients with a known hypersensitivity to it or any local anesthetic agent of the amide type or to other components of Vivacaine® solutions. Local anesthetics should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, an the personnel resources needed for proper management of toxic reactions and related emergencies. Vivacaine® contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Because of the long duration of anesthesia, patients should be cautioned about the possibility of inadvertent trauma to tongue, lips, and buccal mucosa and advised not to chew solid foods or test the anesthetized area by biting or probing. Delay in proper management of dose-related toxicity, underventilation from any cause, and/or altered sensitivity may lead to the development of acidosis, cardiac arrest and, possibly, death. Please see the Package Insert for prescribing information.